- Home
- EFSI vs CABA Comparison
EFSI vs CABA Comparison
Compare EFSI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EFSI
- CABA
- Stock Information
- Founded
- EFSI 1881
- CABA 2017
- Country
- EFSI United States
- CABA United States
- Employees
- EFSI N/A
- CABA N/A
- Industry
- EFSI Major Banks
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EFSI Finance
- CABA Health Care
- Exchange
- EFSI Nasdaq
- CABA Nasdaq
- Market Cap
- EFSI 201.2M
- CABA 174.7M
- IPO Year
- EFSI N/A
- CABA 2019
- Fundamental
- Price
- EFSI $37.30
- CABA $1.95
- Analyst Decision
- EFSI Strong Buy
- CABA Strong Buy
- Analyst Count
- EFSI 2
- CABA 8
- Target Price
- EFSI $39.50
- CABA $12.75
- AVG Volume (30 Days)
- EFSI 8.9K
- CABA 1.4M
- Earning Date
- EFSI 07-24-2025
- CABA 11-13-2025
- Dividend Yield
- EFSI 3.37%
- CABA N/A
- EPS Growth
- EFSI N/A
- CABA N/A
- EPS
- EFSI 1.85
- CABA N/A
- Revenue
- EFSI $61,734,000.00
- CABA N/A
- Revenue This Year
- EFSI N/A
- CABA N/A
- Revenue Next Year
- EFSI $28.84
- CABA N/A
- P/E Ratio
- EFSI $19.82
- CABA N/A
- Revenue Growth
- EFSI N/A
- CABA N/A
- 52 Week Low
- EFSI $28.70
- CABA $0.99
- 52 Week High
- EFSI $37.50
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- EFSI 67.28
- CABA 65.59
- Support Level
- EFSI $36.56
- CABA $1.63
- Resistance Level
- EFSI $37.34
- CABA $2.11
- Average True Range (ATR)
- EFSI 0.47
- CABA 0.12
- MACD
- EFSI -0.11
- CABA 0.04
- Stochastic Oscillator
- EFSI 74.14
- CABA 77.56
About EFSI Eagle Financial Services Inc Common Stock
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.